Imbalanced plasminogen system in lymphangioleiomyomatosis: Potential role of serum response factor

American Journal of Respiratory Cell and Molecular Biology

Volumn 32, Issue 1, 2005, Pages 28-34

  Zhe, Xiaoning ^a   Yang, Yan ^a   Schuger, Lucia ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Lung; Lymphangioleiomyomatosis; Plasminogen; SRF; uPA

Indexed keywords

MATRIX METALLOPROTEINASE; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN; PROTEIN PLG; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME SUBSTRATE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VIVO STUDY; LUNG FIBROBLAST; LUNG PARENCHYMA; LYMPHANGIOLEIOMYOMATOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; UPREGULATION;

CELL PROLIFERATION; CELLS, CULTURED; FIBROBLASTS; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MATRIX METALLOPROTEINASES; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SERUM RESPONSE FACTOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 11144244666     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2004-0289OC     Document Type: Article

References (46)

1. Bernstein SM, Newell JD Jr, Adamczyk D, Mortenson RL, King TE Jr, Lynch DA. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis? Am J Respir Crit Care Med 1995;152:2138-2143.
2. Maziak DE, Kesten S, Rappaport DC, Maurer J. Extrathoracic angiomyolipomas in lymphangioleiomyomatosis. Eur Respir J 1996;9:402-405.
3. Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis: clinical course in 32 patients. N Engl J Med 1990;323:1254-1260.
4. Corrin B, Liebow AA, Friedman PJ. Pulmonary lymphangiomyomatosis: a review. Am J Pathol 1975;79:348-382.
5. Adema GJ, de Boer AJ, Vogel AM, Loenen WA, Figdor CG. Molecular characterization of the melanocyte lineage-specific antigen gp100. J Biol Chem 1994;269:20126-20133.
6. Manabe I, Owens GK. Recruitment of serum response factor and hyperacetylation of histones at smooth muscle-specific regulatory regions during differentiation of a novel P19-derived in vitro smooth muscle differentiation system. Circ Res 2001;88:1127-1134.
7. Stipp CS, Kolesnikova TV, Hemler ME. Functional domains in tetraspanin proteins. Trends Biochem Sci 2003;28:106-112.
8. Rochaix P, Lacroix-Triki M, Lamant L, Pichereaux C, Valmary S, Puente E, Al Saati T, Monsarrat B, Susini C, Buscail L, et al. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Mod Pathol 2003;16:481-490.
9. Zhe X, Schuger L. Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis. J Histochem Cytochem 2004;52:1537-1542.
10. Sullivan EJ. Lymphangioleiomyomatosis: a review. Chest 1998;114:1689-1703.
11. Matsui K, Tatsuguchi A, Valencia J, Yu Z, Bechtle J, Beasley MB, Avila N, Travis WD, Moss J, Ferrans VJ. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000;31:1242-1248.
12. Karbowniczek M, Astrinidis A, Balsara BR, Testa JR, Lium JH, Colby TV, McCormack FX, Henske EP. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003;167:976-982.
13. Bonetti F, Chiodera P. Lymphangioleiomyomatosis and tuberous sclerosis: where is the border? Eur Respir J 1996;9:399-401.
14. Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci USA 2000;97:6085-6090.
15. Goncharova EA, Goncharov DA, Eszterhas A, Hunter DS, Glassberg MK, Yeung RS, Walker CL, Noonan D, Kwiatkowski DJ, Chou MM, Panettieri RA Jr, Krymskaya VP. Tuberin regulates p70 S6 kinase activation and ribosomal protein S6 phosphorylation: a role for the TSC2 tumor suppressor gene in pulmonary lymphangioleiomyomatosis (LAM). J Biol Chem 2002;277:30958-30967.
16. Onda H, Crino PB, Zhang H, Murphey RD, Rastelli L, Gould Rothberg BE, Kwiatkowski DJ. Tsc2 null murine neuroepithelial cells are a model for human tuber giant cells, and show activation of an mTOR pathway. Mol Cell Neurosci 2002;21:561-574.
17. Noonan DJ, Lou D, Griffith N, Vanaman TC. A calmodulin binding site in the tuberous sclerosis 2 gene product is essential for regulation of transcription events and is altered by mutations linked to tuberous sclerosis and lymphangioleiomyomatosis. Arch Biochem Biophys 2002;398:132-140.
18. Valencia JC, Matsui K, Bondy C, Zhou J, Rasmussen A, Cullen K, Yu ZX, Moss J, Ferrans VJ. Distribution and mRNA expression of insulin-like growth factor system in pulmonary lymphangioleiomyomatosis. J Investig Med 2001;49:421-433.
19. Corrin B, Butcher D, McAnulty BJ, Dubois RM, Black CM, Laurent GJ, Harrison NK. Immunohistochemical localization of transforming growth factor-beta 1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. Histopathology 1994;24:145-150.
20. Zhe X, Yang Y, Jakkaraju S, Schuger L. Tissue inhibitor of metalloproteinase-3 downregulation in lymphangioleiomyomatosis: potential consequence of abnormal serum response factor expression. Am J Respir Cell Mol Biol 2003;28:504-511.
21. Kemp PR, Metcalfe JC. Four isoforms of serum response factor that increase or inhibit smooth-muscle-specific promoter activity. Biochem J 2000;345:445-451.
22. Yang Y, Palmer KC, Relan N, Diglio C, Schuger L. Role of laminin polymerization at the epithelial mesenchymal interface in bronchial myogenesis. Development 1998;125:2621-2629.
23. Yang Y, Relan NK, Przywara DA, Schuger L. Embryonic mesenchymal cells share the potential for smooth muscle differentiation: myogenesis is controlled by the cell's shape. Development 1999;126:3027-3033.
24. Browning CL, Culberson DE, Aragon IV, Fillmore RA, Croissant JD, Schwartz RJ, Zimmer WE. The developmentally regulated expression of serum response factor plays a key role in the control of smooth muscle-specific genes. Dev Biol 1998;194:18-37.
25. Belaguli NS, Schildmeyer LA, Schwartz RJ. Organization and myogenic restricted expression of the murine serum response factor gene: a role for autoregulation. J Biol Chem 1997;272:18222-18231.
26. Yang Y, Beqaj S, Kemp P, Ariel I, Schuger L. Stretch-induced alternative splicing of serum response factor promotes bronchial myogenesis and is defective in lung hypoplasia. J Clin Invest 2000;106:1321-1330.
27. Zhang J, O'Shea S, Liu J, Schuger L. Bronchial smooth muscle hypoplasia in mouse embryonic lungs exposed to a laminin beta1 chain antisense oligonucleotide. Mech Dev 1999;89:15-23.
28. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004;279:27896-27904.
29. Sturzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, Wikstrom P. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 1999;9:3147-3152.
30. Collen D. Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology (Am Soc Hematol Educ Program) 2001:1-9.
31. Ferrans VJ, Yu ZX, Nelson WK, Valencia JC, Tatsuguchi A, Avila NA, Riemenschn W, Matsui K, Travis WD, Moss J. Lymphangioleiomyomatosis (LAM): a review of clinical and morphological features. J Nippon Med Sch 2000;67:311-329.
32. Matsui K, Takeda K, Yu ZX, Travis WD, Moss J, Ferrans VJ. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med 2000;124:267-275.
33. Hayashi T, Fleming MV, Stetler-Stevenson WG, Liotta LA, Moss J, Ferrans VJ, Travis WD. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol 1997;28:1071-1078.
34. Shore P, Sharrocks AD. The MADS-box family of transcription factors. Eur J Biochem 1995;229:1-13.
35. Kim S, Ip HS, Lu MM, Clendenin C, Parmacek MS. A serum response factor-dependent transcriptional regulatory program identifies distinct smooth muscle cell sublineages. Mol Cell Biol 1997;17:2266-2278.
36. Carmeliet P, Collen D. Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 1998;91:255-285.
37. Lijnen HR, Collen D. Role of the plasminogen and MMP systems in wound healing. In: Waisman DM, editor. Plasminogen: structure, activation, and regulation. New York: Kluwer Academic/Plenum Publishers; 2003. p. 189-200.
38. Miralles F, Ibanez-Tallon I, Parra M, Crippa M, Blasi F, Besser D, Nagamine Y, Munoz-Canoves P. Transcriptional regulation of the murine urokinase-type plasminogen activator gene in skeletal myoblasts. Thromb Haemost 1999;81:767-774.
39. Chang H, Shyu KG, Lin S, Tsai SC, Wang BW, Liu YC, Sung YL, Lee CC. The plasminogen activator inhibitor-1 gene is induced by cell adhesion through the MEK/ERK pathway. J Biomed Sci 2003;10:738-745.
40. Johansen FE, Prywes R. Identification of transcriptional activation and inhibitory domains in serum response factor (SRF) by using GAL4-SRF constructs. Mol Cell Biol 1993;13:4640-4647.
41. Prywes R, Zhu H. In vitro squelching of activated transcription by serum response factor: evidence for a common coactivator used by multiple transcriptional activators. Nucleic Acids Res 1992;20:513-520.
42. Gineitis D, Treisman R. Differential usage of signal transduction pathways defines two types of serum response factor target gene. J Biol Chem 2001;276:24531-24539.
43. Gutierrez-Fernandez A, Gingles NA, Zhang L, Bannach FG, Jenkins GR, Loskutoff DJ, Parmer RJ, Miles LA. Regulation of plasminogen gene expression. In: Waisman DM, editor. Plasminogen: structure, activation, and regulation. New York: Kluwer Academic/Plenum Publishers; 2003. p. 67-80.
44. Chai J, Tarnawski AS. Serum response factor: discovery, biochemistry, biological roles and implications for tissue injury healing. J Physiol Pharmacol 2002;53:147-157.
45. Kida M, Wakabayashi S, Ichinose A. Expression and induction by IL-6 of the normal and variant genes for human plasminogen. Biochem Biophys Res Commun 1997;230:129-132.
46. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439-444.